Indegene provides digital-led commercialization services for the life sciences industry, including biopharmaceutical, emerging biotech and medical devices companies, that assist them with drug development and clinical trials, regulatory submissions, pharmacovigilance and complaints management, and the sales and marketing of their products. Its solutions enable life sciences companies to develop products, launch them in the market, and drive sales through their life cycle in a more effective, efficient and modern manner. It achieves this by combining over two decades of healthcare domain expertise and fit-for purpose technology.

Indegene major competitors are Syngene Internation., Jubilant Pharmova, Caplin Point Lab, Rubicon Research, Concord Biotech, Alembic Pharma, CORONA Remedies.
Market Cap of Indegene is ₹12,835 Crs.
While the median market cap of its peers are ₹13,982 Crs.

Indegene seems to be less financially stable compared to its competitors.
Altman Z score of Indegene is 15.46 and is ranked 4 out of its 8 competitors.